Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Adverse events due to unnecessary radiation exposure in medical imaging reported in Finland.

Tarkiainen T, Haapea M, Liukkonen E, Tervonen O, Turpeinen M, Niinimäki J.

Radiography (Lond). 2020 Feb 19. pii: S1078-8174(20)30011-0. doi: 10.1016/j.radi.2020.02.002. [Epub ahead of print]

PMID:
32088064
2.

The Risks and Outcomes Resulting From Medication Errors Reported in the Finnish Tertiary Care Units:: A Cross-Sectional Retrospective Register Study.

Laatikainen O, Sneck S, Turpeinen M.

Front Pharmacol. 2020 Jan 17;10:1571. doi: 10.3389/fphar.2019.01571. eCollection 2019.

3.

Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case-control study.

Varpuluoma O, Jokelainen J, Försti AK, Turpeinen M, Timonen M, Huilaja L, Tasanen K.

J Am Acad Dermatol. 2019 Jul;81(1):250-253. doi: 10.1016/j.jaad.2019.02.017. Epub 2019 Feb 13. No abstract available.

PMID:
30771421
4.

Quantitative analysis of 4β- and 4α‑hydroxycholesterol in human plasma and serum by UHPLC/ESI-HR-MS.

Hautajärvi H, Hukkanen J, Turpeinen M, Mattila S, Tolonen A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Nov 15;1100-1101:179-186. doi: 10.1016/j.jchromb.2018.09.028. Epub 2018 Oct 2.

PMID:
30340067
5.

Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.

Varpuluoma O, Försti AK, Jokelainen J, Turpeinen M, Timonen M, Tasanen K, Huilaja L.

J Am Acad Dermatol. 2018 Dec;79(6):1034-1038.e5. doi: 10.1016/j.jaad.2018.05.030. Epub 2018 May 25. Review.

PMID:
29803903
6.

Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.

Varpuluoma O, Försti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, Tasanen K.

J Invest Dermatol. 2018 Jul;138(7):1659-1661. doi: 10.1016/j.jid.2018.01.027. Epub 2018 Feb 7. No abstract available.

7.

New study designs in clinical drug development.

Tenhunen O, Turpeinen M, Kurki P.

Duodecim. 2017;133(6):599-605. Review.

PMID:
29243892
8.

The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis.

Laatikainen O, Miettunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M.

Eur J Clin Pharmacol. 2017 Dec;73(12):1539-1549. doi: 10.1007/s00228-017-2330-3. Epub 2017 Sep 5. Review.

PMID:
28871436
9.

Hospitalizations Due to Adverse Drug Events in the Elderly-A Retrospective Register Study.

Laatikainen O, Sneck S, Bloigu R, Lahtinen M, Lauri T, Turpeinen M.

Front Pharmacol. 2016 Oct 5;7:358. eCollection 2016.

10.

Warfarin-induced calciphylaxis in patients with normal renal function.

Huilaja L, Turpeinen M, Tokola H, Kauma H, Tasanen K, Ikäheimo R.

J Clin Pharm Ther. 2016 Aug;41(4):449-452. doi: 10.1111/jcpt.12411. Epub 2016 Jun 19.

PMID:
27321367
11.

Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.

Lassila T, Mattila S, Turpeinen M, Pelkonen O, Tolonen A.

Rapid Commun Mass Spectrom. 2016 Apr 15;30(7):917-26. doi: 10.1002/rcm.7518.

PMID:
26969934
12.

Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8.

Thomas M, Winter S, Klumpp B, Turpeinen M, Klein K, Schwab M, Zanger UM.

Front Pharmacol. 2015 Nov 4;6:261. doi: 10.3389/fphar.2015.00261. eCollection 2015.

13.

Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.

Uusitalo J, Turpeinen M, Tolonen A, Koskimies P, Lammintausta R, Pelkonen O.

Drug Metab Pers Ther. 2016 Mar;31(1):35-40. doi: 10.1515/dmpt-2015-0020.

PMID:
26581074
14.

Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated.

Lassila T, Hokkanen J, Aatsinki SM, Mattila S, Turpeinen M, Tolonen A.

Chem Res Toxicol. 2015 Dec 21;28(12):2292-303. doi: 10.1021/acs.chemrestox.5b00315. Epub 2015 Nov 11.

PMID:
26558897
15.

Glutathione trapping of reactive drug metabolites produced by biomimetic metalloporphyrin catalysts.

Lassila T, Mattila S, Turpeinen M, Tolonen A.

Rapid Commun Mass Spectrom. 2015 Oct 15;29(19):1849-50. doi: 10.1002/rcm.7290. No abstract available.

PMID:
26331937
16.

Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.

Lassila T, Rousu T, Mattila S, Chesné C, Pelkonen O, Turpeinen M, Tolonen A.

J Pharm Biomed Anal. 2015 Nov 10;115:345-51. doi: 10.1016/j.jpba.2015.07.020. Epub 2015 Jul 26.

PMID:
26263063
17.

Glutathione trapping of reactive drug metabolites produced by biomimetic metalloporphyrin catalysts.

Lassila T, Mattila S, Turpeinen M, Tolonen A.

Rapid Commun Mass Spectrom. 2015 Mar 30;29(6):521-32. doi: 10.1002/rcm.7129. Erratum in: Rapid Commun Mass Spectrom. 2015 Oct 15;29(19):1849-50.

PMID:
26160418
18.

PharmGKB summary: venlafaxine pathway.

Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003. Review. No abstract available.

19.

Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.

Turpeinen M, Uusitalo J, Lehtinen T, Kailajärvi M, Pelkonen O, Vuorinen J, Tapanainen P, Stjernschantz C, Lammintausta R, Scheinin M.

Int J Mol Sci. 2013 Jul 5;14(7):14064-75. doi: 10.3390/ijms140714064.

20.

Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.

Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, Pelkonen O, Scheinin M.

Biopharm Drug Dispos. 2013 Oct;34(7):387-95. doi: 10.1002/bdd.1853. Epub 2013 Aug 15.

PMID:
23852652
21.

Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.

Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O.

Drug Metabol Drug Interact. 2013;28(3):153-61. doi: 10.1515/dmdi-2013-0016.

PMID:
23729558
22.

Cytochrome P450 2B6: function, genetics, and clinical relevance.

Turpeinen M, Zanger UM.

Drug Metabol Drug Interact. 2012;27(4):185-97. doi: 10.1515/dmdi-2012-0027. Review.

PMID:
23152403
23.

Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Hagelberg NM, Saarikoski T, Saari TI, Neuvonen M, Neuvonen PJ, Turpeinen M, Scheinin M, Laine K, Olkkola KT.

Eur J Clin Pharmacol. 2013 Apr;69(4):867-75. doi: 10.1007/s00228-012-1433-0. Epub 2012 Oct 26.

PMID:
23099620
24.

Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations.

Pelkonen O, Turpeinen M, Hakkola J, Abass K, Pasanen M, Raunio H, Vähäkangas K.

Toxicol In Vitro. 2013 Aug;27(5):1578-83. doi: 10.1016/j.tiv.2012.06.002. Epub 2012 Jun 19.

PMID:
22728233
25.

Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.

Korjamo T, Tolonen A, Ranta VP, Turpeinen M, Kokki H.

Front Pharmacol. 2012 Jan 5;2:87. doi: 10.3389/fphar.2011.00087. eCollection 2011.

26.

Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

Mürdter TE, Kerb R, Turpeinen M, Schroth W, Ganchev B, Böhmer GM, Igel S, Schaeffeler E, Zanger U, Brauch H, Schwab M.

Hum Mol Genet. 2012 Mar 1;21(5):1145-54. doi: 10.1093/hmg/ddr543. Epub 2011 Nov 22.

PMID:
22108178
27.

Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children--not too much, not too little.

Turpeinen M, Pelkonen AS, Selroos O, Nikander K, Haahtela T.

Thorax. 2012 Feb;67(2):100-2. doi: 10.1136/thoraxjnl-2011-200246. Epub 2011 Oct 28. No abstract available.

PMID:
22038795
28.

Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs).

Tertti K, Petsalo A, Niemi M, Ekblad U, Tolonen A, Rönnemaa T, Turpeinen M, Heikkinen T, Laine K.

Eur J Pharm Sci. 2011 Oct 9;44(3):181-6. doi: 10.1016/j.ejps.2011.07.002. Epub 2011 Jul 12.

PMID:
21782017
29.

In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Pelkonen O, Turpeinen M, Raunio H.

Clin Pharmacokinet. 2011 Aug;50(8):483-91. doi: 10.2165/11592400-000000000-00000.

PMID:
21740072
30.

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT.

Clin Pharmacol Ther. 2011 Aug;90(2):296-302. doi: 10.1038/clpt.2011.140. Epub 2011 Jun 29.

PMID:
21716267
31.

Lung function, airway remodelling and inflammation in symptomatic infants: outcome at 3 years.

Malmström K, Pelkonen AS, Malmberg LP, Sarna S, Lindahl H, Kajosaari M, Turpeinen M, Saglani S, Bush A, Haahtela T, Jeffery PK, Mäkelä MJ.

Thorax. 2011 Feb;66(2):157-62. doi: 10.1136/thx.2010.139246. Epub 2011 Jan 2.

PMID:
21199817
32.

Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes.

Hokkanen J, Tolonen A, Mattila S, Turpeinen M.

Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17.

PMID:
21168483
33.

True adherence with the Turbuhaler in young children with asthma.

Nikander K, Turpeinen M, Pelkonen AS, Bengtsson T, Selroos O, Haahtela T.

Arch Dis Child. 2011 Feb;96(2):168-73. doi: 10.1136/adc.2010.187724. Epub 2010 Nov 19.

PMID:
21097795
34.

Does tidal exhaled nitric oxide reflect mucosal airway inflammation in infants?

Malmberg LP, Malmström K, Kotaniemi-Syrjänen A, Lindahl H, Kajosaari M, Turpeinen M, Haahtela T, Saglani S, Bush A, Jeffery PK, Pelkonen AS, Mäkelä MJ.

Thorax. 2010 Nov;65(11):1027. doi: 10.1136/thx.2009.128587. Epub 2010 Sep 29. No abstract available.

PMID:
20880878
35.

Unaffected peak inspiratory flow through Turbuhaler during histamine inhalation challenge.

Nikander K, Turpeinen M, Pelkonen AS, Selroos O, Haahtela T.

Allergy. 2011 Feb;66(2):302-3. doi: 10.1111/j.1398-9995.2010.02471.x. Epub 2010 Aug 30. No abstract available.

PMID:
20804463
36.

Bone mineral density in children treated with daily or periodical inhaled budesonide: the Helsinki Early Intervention Childhood Asthma study.

Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen-Backman K, Haahtela T.

Pediatr Res. 2010 Aug;68(2):169-73. doi: 10.1203/00006450-201011001-00329.

PMID:
20485203
37.

An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes.

Abass K, Turpeinen M, Pelkonen O.

J Environ Sci Health B. 2009 Aug;44(6):553-63. doi: 10.1080/03601230902997766.

PMID:
20183062
38.

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM.

Front Pharmacol. 2010 Nov 2;1:129. doi: 10.3389/fphar.2010.00129. eCollection 2010.

39.

Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells.

Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2010 Mar;38(3):516-25. doi: 10.1124/dmd.109.030197. Epub 2009 Dec 17.

PMID:
20019244
40.

Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes.

Volotinen M, Korjamo T, Tolonen A, Turpeinen M, Pelkonen O, Hakkola J, Mäenpää J.

Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):302-9. doi: 10.1111/j.1742-7843.2009.00487.x. Epub 2009 Nov 11.

41.

Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis.

Pelkonen O, Tolonen A, Rousu T, Tursas L, Turpeinen M, Hokkanen J, Uusitalo J, Bouvier d'Yvoire M, Coecke S.

ALTEX. 2009;26(3):214-22.

42.

Skin thickness in children treated with daily or periodical inhaled budesonide for mild persistent asthma. The Helsinki early intervention childhood asthma study.

Turpeinen M, Raitio H, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen-Backman K, Haahtela T.

Pediatr Res. 2010 Feb;67(2):221-5. doi: 10.1203/PDR.0b013e3181c6e574.

PMID:
19858777
43.

Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children.

Obase Y, Rytilä P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, Mäkelä M, Saarialho-Kere U, Selroos O, Sorsa T, Haahtela T.

Int Arch Allergy Immunol. 2010;151(3):247-54. doi: 10.1159/000242362. Epub 2009 Sep 29.

PMID:
19786805
44.

From known knowns to known unknowns: predicting in vivo drug metabolites.

Pelkonen O, Tolonen A, Korjamo T, Turpeinen M, Raunio H.

Bioanalysis. 2009 May;1(2):393-414. doi: 10.4155/bio.09.32. Review.

PMID:
21083174
45.

Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.

Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, Zanger UM.

Pharmacogenomics. 2009 Apr;10(4):579-99. doi: 10.2217/pgs.09.7.

46.

Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.

Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O.

Toxicol In Vitro. 2009 Jun;23(4):748-53. doi: 10.1016/j.tiv.2009.03.008. Epub 2009 Mar 26.

PMID:
19328226
47.

Budesonide improves decreased airway conductance in infants with respiratory symptoms.

Pelkonen AS, Malmström K, Malmberg LP, Sarna S, Turpeinen M, Kajosaari M, Haahtela T, Mäkelä MJ.

Arch Dis Child. 2009 Jul;94(7):536-41. doi: 10.1136/adc.2007.132100. Epub 2009 Mar 1.

PMID:
19254906
48.

A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.

Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM.

Drug Metab Dispos. 2009 May;37(5):1017-24. doi: 10.1124/dmd.108.025700. Epub 2009 Feb 9.

PMID:
19204080
49.

Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.

Tolonen A, Turpeinen M, Pelkonen O.

Drug Discov Today. 2009 Feb;14(3-4):120-33. doi: 10.1016/j.drudis.2008.11.002. Epub 2008 Dec 26. Review.

PMID:
19059358
50.

Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column.

Petsalo A, Turpeinen M, Pelkonen O, Tolonen A.

J Chromatogr A. 2008 Dec 26;1215(1-2):107-15. doi: 10.1016/j.chroma.2008.10.122. Epub 2008 Nov 7.

PMID:
19019380

Supplemental Content

Loading ...
Support Center